Corporate | Regen Lab

Regenlab news article

par Marc Antoine Aimé | Août 17, 2026 | Corporate

The Future of Regenerative Medicine: Regen Lab CEO Antoine Turzi in Conversation with SmartTRAK ; Regen lab CEO Antoine Turzi discusses the evolution of regenerative medicine and the company's research focus in interview with SmartTRAK 3 Regenlab founder and...

RegenLab Welcomes OSP & SHE Delegation to BioArk Tech Park

par Marc Antoine Aimé | Juin 22, 2026 | Corporate

Education, Innovation and Regenerative Medicine: RegenLab Welcomes OSP (Office d’orientation scolaire, professionnelle et de carrière) & SHE (Service des hautes écoles ) Delegation to BioArk Tech Park ; Strengthening connections between education, innovation and...

RegenLab and MSFpharm Strengthen Their Partnership with a Scientific Event in Belgrade

par Marc Antoine Aimé | Juin 10, 2026 | Congress, Corporate

RegenLab and MSFpharm Strengthen Their Partnership with a Scientific Event in Belgrade From Regeneration to Collagen Stimulation: Advanced Clinical Applications of RegenLab BCT & Cellular Matrix will take place on 27 June 2026, bringing together expert faculty, live...

RegenLab USA & MiMedx: Exclusive U.S. Distribution for RegenKit®-Wound Gel

par Marc Antoine Aimé | Jan 13, 2026 | Corporate

RegenLab USA and MiMedx Announce Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel ; “We are thrilled to partner with MIMEDX to bring RegenKit®-Wound Gel to patients across the United States, » said Franck Maingonnat, VP of Business Development at Regen...

PRP Preparation in Europe | CE Marking, Safety & Standardisation

par Marc Antoine Aimé | Jan 6, 2026 | Corporate

See why the Regenlab patented system is not just another tube Closed-System PRP Preparation: Improving Safety and Standardisation in Clinic ; In daily practice, not all tubes are equivalent when it comes to preparing PRP (Platelet-Rich Plasma). Beyond appearance, the...

ESSM-REGENLAB Webinar Series #2

par Marc Antoine Aimé | Juin 30, 2025 | Corporate

The replay of the ESSM Webinar Series 2024 session, hosted in collaboration with RegenLab, is now available to watch. Female regenerative therapies. State of the art. Watch replay  Moderators Giovanni CoronaMD PhDEndocrinology Unit Prof Dr Daniar...

« Entrées précédentes



RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.



RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

CM-OA

CM-Skin



RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.



RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).



RegenWound

RegenWound is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardised and reproducible approach for clinical use.



Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.



Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.



Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.